middle.news
Immutep Resumes Trading After Key Phase III Trial Update
9:06am on Friday 13th of March, 2026 AEDT
•
Healthcare
Read Story
Immutep Resumes Trading After Key Phase III Trial Update
9:06am on Friday 13th of March, 2026 AEDT
Key Points
Trading suspension lifted immediately
Interim futility analysis results released
TACTI-004 (KEYNOTE-F91) Phase III trial update
Focus on lead candidate eftilagimod alfa
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Immutep (ASX:IMM)
OPEN ARTICLE